Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

RITE AID ACCELERATING INTO AUTO PARTS RETAILING WITH ACQUISITION OF ADAP, a 32-store automotive supply chain operating in New England and based in Avon, Mass. In a March 20 press release announcing the merger, Rite Aid characterized ADAP as "the largest discount automotive after-market retailer in New England." The automotive parts retailer had sales of $34.2 mil. in 1983, which generated net earnings of $1.3 mil., Rite Aid said. The price of the acquisition was not disclosed. Commenting on the acquisition, Rite Aid noted that ADAP "will provide the talent and experience required for expansion in this highly desirable area of specialty retailing." In buying a retail auto parts business, Rite Aid is following a path blazed by several drug chains including Dart and Hook, mutual owners of Trak Auto, and Perry, which last August purchased the 50-store Fleenor's auto parts retail business. Perry is generally credited with being the first drug chain to move into auto parts retailing within its drug store units. The chain later opened 11 stand-alone Auto Works stores before purchasing the Indiana-based Fleenor's last year. Assuming that the price paid for ADAP as a ratio to sales is roughly similar to what Perry paid for Fleenor's, the price tag for ADAP was probably in the $6 mil.-$8 mil. range -- and possibly higher since ADAP was considerably more profitable at the time of purchase.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts